26. Srinivas GB, Walker A, Rippke B. USDA regulatory guidelines and
practices for veterinary Leptospira vaccine potency testing. Biologicals
2013;41:298–302.
27. Wilson S, Stirling C, Thomas A, et al. A new multivalent (DHPPi/L4R)
canine combination vaccine prevents infection, shedding and clinical
signs following experimental challenge with four Leptospira serovars.
Vaccine 2013;31:3131–4.
28. Eric Klaasen HL, Adler B. Recent advances in canine leptospirosis:
focus on vaccine development. Vet Med (Aukl) 2015;6:245–60.
29. Sonrier CB, Michel V, Ruvoe
En-Clouet N, et al. Evidence of cross-
protection within Leptospira interrogans in an experimental model.
Vaccine 2001;19:86–94.
30. Grosenbaugh DA, Pardo MC. Fifteen-month duration of immunity for
the serovar Grippotyphosa fraction of a tetravalent canine leptospirosis
vaccine. Vet Rec 2018;182:665.
31. Klaasen HL, Molkenboer MJ, Vrijenhoek MP, et al. Duration of immu-
nity in dogs vaccinated against leptospirosis with a bivalent inactivated
vaccine. Vet Microbiol 2003;95:121–32.
32. Minke JM, Bey R, Tronel JP, et al. Onset and duration of protective
immunity against clinical disease and renal carriage in dogs provided
by a bi-valent inactivated leptospirosis vaccine. Vet Microbiol 2009;137:
137–45.
33. Schreiber P, Martin V, Grousson D, et al. One-year duration of immu-
nity in dogs for Leptospira Interrogans serovar Icterohaemorrhagiae
after vaccination. Int J Appl Res Vet Med 2012;10:305–10.
34. Wilson S, Stirling C, Thomas A, et al. Duration of immunity of a mul-
tivalent (DHPPi/L4R) canine vaccine against four Leptospira serovars.
Vaccine 2013;31:3126–30.
35. Bouvet J, Cariou C, Valfort W, et al. Efficacy of a multivalent DAPPi-
Lmulti canine vaccine against mortality, clinical signs, infection, bacte-
rial excretion, renal carriage and renal lesions caused by Leptospira
experimental challenges. Vaccine Rep 2016;6:23–8.
36. Lee HS, Guptill L, Johnson AJ, et al. Signalment changes in canine lep-
tospirosis between 1970 and 2009. J Vet Intern Med 2014;28:294–9.
37. Ricardo T, Previtali MA, Signorini M. Meta-analysis of risk factors for
canine leptospirosis. Prev Vet Med 2020;181:105037.
38. Iverson SA, Levy C, Yaglom HD, et al. Clinical, diagnostic, and epide-
miological features of a community-wide outbreak of canine leptospiro-
sis in a low-prevalence region (Maricopa County, Arizona). JAmVet
Med Assoc 2021;258:616–29.
39. Azocar-Aedo L, Monti G. Meta-analyses of factors associated with lep-
tospirosis in domestic dogs.
Zoonoses Public Health 2016;63:328–36.
40. Martin LE, Wiggans KT, Wennogle SA, et al. Vaccine-associated Lepto-
spira antibodies in client-owned dogs. JVetInternMed2014;28:789–92.
41. Kodjo A, Calleja C, Loenser M, et al. A rapid in-clinic test detects acute
leptospirosis in dogs with high sensitivity and specificity. Biomed Res
Int 2016;2016:3760191.
42. Lizer J, Grahlmann M, Hapke H, et al. Evaluation of a rapid IgM
detection test for diagnosis of acute leptospirosis in dogs. Vet Rec 2017;
180:517.
43. Midence J, Leutenegger C, Chandler A, et al. Effects of recent Lepto-
spira vaccination on whole blood real-time PCR testing in healthy
client-owned dogs. JVetInternMed2012;26:149–52.
44. St okes W, Srinivas G, McFarland R, et al. Report on the interna-
tional workshop on alternative methods for Leptospira vaccine
potency testing: state of the science and t he way forward. Biologicals
2013;41:279–94.
45. Troia R, Balboni A, Zamagni S, et al. Prospective evaluation of rapid
point-of-care tests for the diagnosis of acute leptospirosis in dogs. Vet J
2018;237:37–42.
46. Mwachui MA, Crump L, Hartskeerl R, et al. Environmental and behav-
ioural determinants of leptospirosis transmission: a systematic review.
PLoS Negl Trop Dis 2015;9:e0003843.
47. Martins G, Penna B, Lilenbaum W. The dog in the transmission of
human leptospirosis under tropical conditions: victim or villain? Epide-
miol Infect 2012;140:207–8; author reply 208–9.
48. Major A, Schweighauser A, Francey T. Increasing incidence of canine
leptospirosis in Switzerland. Int J Environ Res Public Health 2014;11:
7242–60.
49. Gay N, Soup
e-Gilbert M-E, Goarant C. Though not reservoirs, dogs
might transmit Leptospira in New Caledonia. Int J Environ Res Public
Health 2014;11:4316–25.
50. Klaasen HL, van der Veen M, Molkenboer MJ, et al. A novel tetravalent
Leptospira bacterin protects against infection and shedding following
challenge in dogs. Vet Rec 2013;172:181.
51. Bouvet J, Lemaitre L, Cariou C, et al. A canine vaccine against Lepto-
spira serovars Icterohaemorrhagiae, Canicola and Grippotyphosa pro-
vides cross protection against Leptospira serovar Copenhageni. Vet
Immunol Immunopathol 2020;219:109985.
52. Moore GE, Guptill LF, Ward MP, et al. Adverse events diagnosed
within three days of vaccine administration in dogs. JAmVetMed
Assoc 2005;227:1102–
8.
53. Yao PJ, Stephenson N, Foley JE, et al. Incidence rates and risk factors
for owner-reported adverse events following vaccination of dogs that
did or did not receive a Leptospira vaccine. J Am Vet Med Assoc 2015;
247:1139–45.
54. Robbins H. Adverse events in dogs given Leptospira vaccine. Vet Rec
2017;180:257.
55. Eisen L. Vector competence studies with hard ticks and Borrelia burg-
dorferi sensu lato spirochetes: a review. Ticks Tick Borne Dis 2020;11:
101359.
56. O’Bier NS, Hatke AL, Camire AC, et al. Human and veterinary vac-
cines for Lyme disease. Curr Issues Mol Biol 2021;42:191–222.
57. Honsberger NA, Six RH, Heinz TJ, et al. Efficacy of sarolaner in the
prevention of Borrelia burgdorferi and Anaplasma phagocytophilum
transmission from infected Ixodes scapularis to dogs. Vet Parasitol
2016;222:67–72.
58. Kr
€
amer F, H
€
usken R, Kr
€
udewagen EM, et al. Prevention of transmis-
sion of Borrelia burgdorferi sensu lato and Anaplasma phagocytophilum
by Ixodes spp. ticks to dogs treated with the Seresto
V
R
collar (imidaclo-
prid 10%1 flumethrin 4.5%). Parasitol Res 2020;119:299–315.
59. Little S, Braff J, Place J, et al. Canine infection with Dirofilari a immitis,
Borrelia burgdorferi, Anaplasma spp., and Ehrlichia spp. in the United
States, 2013–2019. Parasit Vectors 2021;14:1–16.
60. Herrin BH, Peregrine AS, Goring J, et al. Canine infection with Borrelia
burgdorferi, Dirofilaria immitis, Anaplasma spp. and Ehrlichia spp. in
Canada, 2013–2014. Parasit Vectors 2017;10:1–9.
61. Evason M, Stull JW, Pearl DL, et al. Prevalence of Borrelia burgdorferi,
Anaplasma spp., Ehrlichia spp. and Dirofilaria immitis in Canadian dogs,
2008 to 2015: a repeat cross-sectional study. Parasit Vectors 2019;12:64.
62. Liu Y, Nordone SK, Yabsley MJ, et al. Quantifying the relationship
between human Lyme disease and Borrelia burgdorferi exposure in
domestic dogs. Geospatial Health 2019;14:111–20.
63. Littman MP, Gerber B, Goldstein RE, et al. ACVIM consensus
update on Lyme borreliosis in dogs and cats. JVetInternMed2018;
32:887–903.
64. Dambach D, Smith C, Lewis R, et al. Morphologic, immunohistochemi-
cal, and ultrastructural characterization of a distinctive renal lesion in
dogs putatively associated with Borrelia burgdorferi infection: 49 cases
(1987–1992). Vet Pathol 1997;34:85–96.
16 JAAHA | 58:5 Sep/Oct 2022